Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • icd20
    Junior Member
    • Dec 2020
    • 1

    #1

    Help with ERV analysis

    Hi,
    Very new to this! Apologies if not enough information given.
    I'm trying to count the change in ERV expression before and after treatment of human cell lines with a drug. I have been using the gEVE database, which provides a GTF annotation for human genomes (http://geve.med.u-tokai.ac.jp/download/).
    My pipeline is: generate genome indices using STAR --> trim reads (fasta files) using trimmomatic --> sort, remove blacklisted regions --> align trimmed reads to genome using STAR again --> count reads using featureCounts.

    All seems fine except counting reads: I get a very low percentage of assigned reads (usually 0.1%) and these are mainly due to "Unassigned_NoFeatures". This is my input for featureCounts:
    fc_ERV <- featureCounts(files=filenames, annot.ext="Hsap38.geve.v1.gtf", isGTFAnnotationFile=TRUE, GTF.featureType="CDS", countMultiMappingReads=TRUE, genome='Homo_sapiens.GRCh38.dna.primary_assembly.fa', isPairedEnd=TRUE,nthread=20)
    I have used "GTF.featureType="CDS"" because the GTF from gEVE does not have an exon column, only CDS.
    Any ideas on what I'm doing wrong? I am new to Bioinformatics, any help would be much appreciated.
    Last edited by icd20; 02-08-2021, 07:53 AM.

Latest Articles

Collapse

  • SEQadmin2
    Beyond CRISPR/Cas9: Understand, Choose, and Use the Right Genome Editing Tool
    by SEQadmin2



    CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).

    Despite this, “CRISPR helped turn genome editing from a specialized technique into
    ...
    07-31-2026, 11:01 AM
  • SEQadmin2
    Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
    by SEQadmin2


    Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

    The systematic characterization of the human proteome has
    ...
    07-20-2026, 11:48 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by SEQadmin2, 08-06-2026, 07:41 AM
0 responses
23 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 08-03-2026, 10:13 AM
0 responses
35 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-31-2026, 02:55 AM
0 responses
43 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-24-2026, 12:17 PM
0 responses
26 views
0 reactions
Last Post SEQadmin2  
Working...